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A B S T R A C T
Background: Intact immune responses to cytomegalovirus (CMV) and Epstein-Barr virus (EBV) represent
a biologically and clinically relevant correlate of ‘immunological ﬁtness’ in humans. However, there is a
lack of knowledge concerning anti-EBV or anti-CMV responses in patients with pulmonary tuberculosis
(TB), in whom aberrant immune responses may promote progression of clinical disease.
Methods: Venous blood samples were obtained at the time of (sputum smear positive) pulmonary TB
diagnosis. A whole blood assay was performed by exposing PBMCs (peripheral blood mononuclear cells)
to a panel of infectious antigens, including CMV, EBV and mycobacterial proteins. Cell culture
supernatants were collected after seven days and interferon gamma (IFN-g) was measured using a
sandwich ELISA. Patients received standard ﬁrst line anti-tuberculosis rifampicin (R)/isoniazid (H)/
ethambutol (E)/pyrazinamide (Z) for two months followed by RH for four months.
Results: PBMCs from cured patients (after treatment completion) exhibited signiﬁcantly stronger IFN-g
responses to CMV (p=0.035), EBV (p=0.006) or Mycobacterium tuberculosis ESAT-6 (p = 0.043) at the time
of diagnosis as compared to patients who succumbed to TB during treatment. IFN-g responses to other
viral (H5N1, HSV-1) as well as other mycobacterial (Ag85A, Rv2958c, Rv0447c) antigens were not found
to be signiﬁcantly different among patients who were cured or those who succumbed to TB.
Conclusions: Increased cellular immune responses to CMV and EBV antigens at the time of diagnosis of
pulmonary tuberculosis are associated with increased survival after a standard six months anti-TB
therapy. CVM and EBV antigens may represent “intrinsic markers for immune ﬁtness” and guide
improved TB therapies including host-directed therapies.
© 2017 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Intact cellular immune responses to Epstein-Barr virus (EBV)
and cytomegalovirus (CMV) reﬂect the general immunological
ﬁtness.1,2 Compromised immune responses to either CMV or EBV
are linked to disease progression in patients with cancer or in
patients after transplantation.1,2 Progression of Mycobacterium
tuberculosis (M. tb) infection to clinical TB disease is associated
with aberrant host immune responses.3 Increased T-cell reactivity
to mycobacterial puriﬁed protein derivative (PPD) has been
reported in individuals without active TB, irrespective of a
concomitant HIV infection as reﬂected by strong Th1 responses
(interferon gamma (IFN-g)) and tumour necrosis factor alpha
(TNF-a) production in response to CMV, while EBV-speciﬁc IFN-
g/TNF-a responses were generally weaker than CMV or PPD
responses.4,5 The immune reactivity to EBV and CMV among
patients with active pulmonary TB has not been explored,
particularly in the context of survival. Using whole blood assays
and enzyme-linked immunosorbent assay (ELISA), we present here
the IFN-g responses in peripheral blood of patients pulmonary TB
to CMV and EBV antigens versus survival in the course of standard
anti-TB therapy.Table 1
List of whole blood assay antigens.
Antigen Source pathogen Description of the target antig
EBNA1 Epstein-Barr virus (EBV) Epstein-Barr nuclear antigen 1,
CMV pp65 Cytomegalovirus (CMV) CMV tegument protein (UL83)
PPD Mycobacterium tuberculosis (M. tb)
H37Ra
Puriﬁed cellular protein extrac
ESAT-6 M. tb H37Rv Pore-forming toxin secreted b
Ag85A M. tb H37Rv Mycolyl transferase, a domina
Rv2957 M. tb H37Rv Cytoplasmic glycosyltransferas
Rv2958c M. tb H37Rv Cytoplasmic glycosyltransferas
Rv0447c M. tb H37Rv Cytoplasmic cyclopropane-fatt
maintenance
HSV-
1 antigen
Herpes simplex virus 1 (HSV-1) HSV-1 glycoprotein (gG)
H5N1 antigen Inﬂuenza virus Recombinant H5N1 Inﬂuenza-
HIV env Human immunodeﬁciency virus
(HIV)
gp160 protein involved in vira
HIV gag HIV group-speciﬁc antigen involve
Table 2
Comparison of baseline characteristics among patients with tuberculosis according to 
Survived
Missing n(%)/med
% Male sex 0 144 (67,6
Age (years) 1 36,0 
CD4+ at TB diagnosis (cell/mL) 21 459.0 
% HIV infected 0 81 (38,0)
% on Fluconazole treatment 43 11 (59.78
HIV and anti-retroviral therapy 0
HIV un-infected 132 (62,0
HIV infected ART* prior to anti-TB 31 (14,6)
HIV infected ART* during anti-TB 47 (22,1)
HIV infected no ART at any time of anti-TB 3 (1,4) 
MTB load 0
Scanty 28 (13,14
1+ 57 (26,76
2+ 60 (28,17
3+ 68 (31,92
Smoking status 4
Never smoked 156 (74,3
Ever smoked 54 (25,7)
* ARV  Antiretroviral therapy.Methods
Ethical clearance was granted by the Muhimbili University of
Health and Allied Health sciences (MUHAS) Senate Research and
Publications committee (Ref. No. RP/AEC/VOL.XII).
Sputum smear positive pulmonary tuberculosis (PTB) patients
were recruited at diagnosis and prior to initiating anti-TB therapy
after obtaining written informed consent. The following selection
criteria applied: 18 years and above; conﬁrmed for pulmonary TB
by M. tb smear positivity ; with or without HIV co-infection;
without previous TB episode; visiting one of the three study sites in
Dar-es-Salaam: Mnazi mmoja health centre, Mwananyamala or
Amana municipal hospitals. For the whole blood assay, venous
blood drawn at TB diagnosis was diluted 1:1.5 in RPMI medium
supplemented with 10% foetal calf serum (FCS) and 1% antibiotics
and cultured in micro-titre plates containing a panel of twelve
infectious antigens, each at 1 mg/ml (Table 1). The plates were
incubated at 37 C with 5% CO2 over a 7-day period, after which
supernatants were harvested and stored at 80 C. IFN-g content
was measured in the supernatants using a commercially available
ELISA kit (Mabtech, Sweden).en
 involved in negative regulation of MHC class antigen processing and presentation
 involved in immune regulation in the host
t of an attenuated M. tb strain (H37Ra)
y pathogenic mycobacteria, B- and T-cell target
nt secreted antigen, serves as B- and T-cell target
e involved in mycobacterial cell wall synthesis and maintenance
e involved in mycobacterial cell wall synthesis and maintenance
y-acyl-phospholipid synthase involved in mycobacterial cell wall synthesis and
A Virus Vietnam 1203/04
l replication
d in viral particle assembly
vital status at the end of treatment with anti-tuberculosis (n = 234).
 (n = 213) Died (n = 21) Total (n = 234) P
ian n(%)/median n(%)/median
) 11 (52,4) 155 (66,2) 0.23
35,00 36,00 0.69
342 425 0.06
 15 (71,4) 96 (41,0) 0.004
) 1 (14.29) 12 (6.28) 0.370
) 6 (28,6) 138 (59,0) 0.0001
 2 (9,5) 33 (14,1)
 10 (47,6) 57 (24,4)
3 (14,3) 6 (2,6)
5) 2 (9,52) 30 (12,82) 0.972
) 6 (28,57) 63 (26,92)
) 6 (28,57) 66 (28,21)
) 7 (33,33) 75 (32,05)
) 19 (95,0) 175 (76,1) 0.115
 1 (5,0) 55 (26.1)
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requires combination of isoniazid, rifampicin, ethambutol and
pyrazinamide for two months followed by rifampicin and isoniazid
for 4 months. All patients had direct observed therapy at the most
convenient clinic or with a treatment supporter. Drug adherence in
our cohort was 97.3%.
Statistical analysis was performed with the SPSS software and
GraphPad Prism 6 was used to create graphs. Mann-Whitney U test
was used to test the median difference between IFN-g concentra-
tion between cured/survivors and those who died during
tuberculosis treatment (all-cause mortality). Reported gamma
interferon results are absolute values after subtracting backgroundFigure 1. IFN-g responses to viral and mycobacterial antigens in whole blood assay. Dilu
and mycobacterial antigens over a 7-day period. Supernatants were harvested after 7 day
the mean (SEM) (n = 234 pulmonary TB patients).gr1reactivity of each individual against medium value. P value of less
than 0.05 was considered signiﬁcant.
Results
We report a total of 21 deaths which occurred during the course
of follow up; most TB patients (72%) who exhibited a compromised
IFN-g response died within the ﬁrst three months of anti-TB
treatment. Meanwhile, 213 patients with tuberculosis were
successfully treated. With exception of HIV, clinical and demo-
graphic characteristics did not differ among patients who were
cured compared to those who died, particularly the two patientted venous blood from patients with pulmonary TB were exposed to a panel of viral
s for IFN-g measurement by sandwich ELISA. Shown are means and standard error of
T. Nagu et al. / International Journal of Infectious Diseases 56 (2017) 136–139 139groups who exhibited similar mycobacterial load (Table 2). Among
those patients who succumbed, 15 had HIV co-infection while 6
had no HIV infection (Table 2).
Statistically signiﬁcant differences in IFN-g responses in
peripheral blood between patients who died versus those who
survived and were cured of TB were observed concerning the
following antigens: ESAT-6 (0.043), CMV pp65 (p = 0.035) and
EBNA1 (p = 0.006) (Figure 1). We observed a similar trend as we
dichotomised IFN-g responses by HIV infection; however, signiﬁ-
cantly higher IFN-g responses to CMV (p = 0.004), EBV (p = 0.05)
and ESAT6 (p = 0.003) were demonstrated among (surviving)
patients co-infected with TB/HIV, as compared to TB/HIV patients
who died.
Other infectious antigens with a similar trend, but no statistical
difference were Rv2958c, Rv0447c, PPD, Ag85A, herpes simplex
virus 1 (HSV-1) glycoprotein and HIV env protein. Patients who
survived 6 months of TB therapy produced approximately three
times more IFN-g in response to the above-mentioned antigens as
compared to those who died during the course of TB therapy.
Discussion
We show, to our knowledge, for the ﬁrst time that impaired
cellular immune responses to ESAT-6, CMV (pp65) or EBV (EBNA-
1), reﬂected by IFN-g production in peripheral blood are associated
with death among TB patients during anti-TB treatment. Intact T-
cell responses to CMV and/or EBV are integral to general
immunological ﬁtness. EBNA-1 represents a constitutively
expressed latency-associated antigen of EBV, it is also a CD4 T
cell target that induces potent Th1 responses in EBV-positive
individuals.6 CMV pp65 is a dominant T-cell target that also elicits
strong antibody responses; anti-CMV pp65 reactivity is considered
to represent a clinically and biologically relevant biomarker to
gauge the overall anti-CMV response in humans.1
ESAT-6 is a virulence factor expressed and secreted by
pathogenic mycobacteria including M. tb, and a strong T-cell
target.7 The QuantiFERON-TB Gold IFN-g-release assay for latent
TB infection (LTBI) diagnosis is based on peripheral blood T-cell
responses to ESAT-6 and its chaperone, CFP10,8 while several
clinical TB vaccine candidates incorporate ESAT-6 in their design.9
Taken together, impaired cellular responses to EBV, CMV and ESAT-
6 during the intensive, ﬁrst, phase of anti-TB therapy is a potential
predictor of poor survival among pulmonary TB patients. Although
statistically not signiﬁcant, reduced IFN-g responses to the M. tb
antigens (Rv2958c, Rv0447c and Ag85A) as well as to PPD8 in
PBMCs from patients who died during treatment, suggests that
these antigens may play a role in orchestrating protective cellular
immune responses in pulmonary TB.
We believe it is clinically and biologically relevant to test for
EBV/CMV DNA in the blood samples of TB patients in future studies
and link this information to their respective anti- EBV/CVM
directed immune reactivity. Gauging immune responses directed
against CMV or EBV as markers of ‘immune-ﬁtness’ may aid in
identifying patients who are at risk to succumb to TB, or are
effectively able to combat M. tb  without overt organ/tissue
(pulmonary) damage, which also associates with long-term
aberrant inﬂammation and immune-exhaustion.3,10 In order to
discern whether CMV/EBV responses are a reﬂection of prior oracute infection, it would add value to assess EBV and CMV DNA
viral load; this may be considered a limitation of this study.
Conclusion
CMV, EBV and ESAT-6 – speciﬁc IFN-g responses in TB patients
with pulmonary TB at the time point of diagnosis correlate with
cure and survival during anti-TB therapy. We recommendd future
studies concerning i) CVM/EBV-vectored vaccines, and ii) gauging
CMV/EBV responses as prognostic markers to identify patients at
high risk to succumb to TB disease and to identify time points for
Host-Directed Therapies (HDTs). ‘Immune competence’ may be
measured using anti-EBV or anti-CMV cellular immune responses
in individuals using this (anti-EBV/anti-CMV) immunological
‘setpoint’ as a clinically and biological relevant parameter for ‘T-
cell ﬁtness’.
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